Arvinas leader departs under a Pfizer-shaped cloud
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Early validation for in vivo Car-T
ESO-T01 delivers its first four multiple myeloma case reports.
Safety remains the key metric for Cogent
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
Amgen and Zai Lab eye a gastric niche
Adverse events will be closely watched when full data are reported.
BeOne tries to repeat the inhibitor-degrader double
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
BeOne also needs B7-H4 biomarkers
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
A solid tumour Car-T first?
Satri-cel is filed for gastric cancer approval in China.
